Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Moxifloxacin (Primary) ; Moxifloxacin (Primary) ; Amoxicillin/clavulanic acid; Ertapenem
  • Indications Bacterial infections; Intra-abdominal infections
  • Focus Adverse reactions; Registrational
  • Acronyms MOXIPEDIA
  • Sponsors Bayer

Most Recent Events

  • 10 Jul 2019 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
  • 18 Jan 2018 Results assessing safety and also the efficacy of moxifloxacin (MXF) in children with complicated intra-abdominal infections, were published in the Pediatric Infectious Disease Journal.
  • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top